### PRESIDENTIAL SESSION 1: THE CHALLENGES OF BUILDING REAL COOPERATION TO IMPLEMENT PRECISION ONCOLOGY PROGRAMS: A LONG AND WINDING ROAD

**Chairs:** John Mendelsohn, UT-MDACC, USA, Chairman of WIN Consortium; Jean-Charles Soria, MedImmune, USA

#### Keynote Lecture: The TAPUR family of clinical trials: building a global data sharing platform in Precision Oncology
Richard L. Schilsky, American Society of Clinical Oncology (ASCO®), USA

#### Making Cancer History all together
Stephen M. Hahn, The University of Texas MD Anderson Cancer Center, USA

#### U.S. National Cancer Institute perspective on Precision Oncology
James H. Doroshow, National Cancer Institute (NCI), USA

#### Beyond standard of care: the next steps of Precision Oncology - an ESMO perspective
Josep Tabernero, Vall d’Hebron Institute of Oncology (VHIO), Spain, President European Society for Medical Oncology (ESMO), Switzerland

#### A view from the European Union on the international collaborations and the future of the Framework programmes
Cornelius Schmaltz, Head of Unit Health Research Strategy, Directorate General for Research and Innovation at the European Commission in Brussels, Belgium

#### Open Forum and Debate with the audience: The key issues of worldwide cooperation

- Technology and conceptual breakthroughs
- Industry or academic sponsored research
- Funding of clinical trials
- Publication policies

**Moderators:**
Lisa Hutchinson, Foundation for World Health (FWH), UK, WIN Consortium
Jean-Charles Soria, MedImmune, USA

**Panel:**
James H. Doroshow, NCI, USA
Stephen M. Hahn, UT-MDACC, USA
John Mendelsohn, UT-MDACC, USA
Richard L. Schilsky, ASCO, USA
Josep Tabernero, VHIO, Spain, ESMO

### SESSION 2: THE NEXT FRONTIER OF THERAPEUTICS IN NEWLY DIAGNOSED PATIENTS: STANDARD OF CARE OR MODERN BIOMARKER DRIVEN PRECISION ONCOLOGY?

**Chairs:** Razelle Kurzrock, UCSD, USA; Josep Tabernero, VHIO, Spain

#### Keynote lecture: Preventive and curative healthcare: the next frontier for Precision Oncology
John Wilden, Foundation for World Health (FWH), UK

#### A new world of early diagnosis to defeat Non-Small Cell Lung Carcinoma (NSCLC)
The WIN Consortium BOOSTER trial for identification and validation of new blood biomarkers for NSCLC
Amir Onn, Sheba Medical Center, Israel

#### Lessons from long-term survey of Stage I NSCLC
Harvey I. Pass, New York University, NYU Langone Health, USA

#### Keynote Lecture: Patients’ expectations and hopes
Ellen V. Sigal, Friends of Cancer Research, USA

#### Newly diagnosed breast cancer at the frontier of precision oncology
Laura Esserman, University of California San Francisco (UCSF), USA
**MONDAY JUNE 25, 2018 - CONTINUED**

**Open forum and debate with the audience:** Next frontiers of therapeutics  
**Moderators:**  
Razelle Kurzrock, UCSD, USA  
Josep Tabernero, VHIO, Spain  

**Panel:**  
Laura Esserman, UCSF, USA  
Amir Onn, Sheba Medical Center, Israel  
Harvey I. Pass, NYU Langone Health, USA  
Ellen V. Sigal, Friends of Cancer Research, USA

**WELCOME RECEPTION, NETWORKING AND POSTER VIEWING** running at the same time as  
**MEET THE PROFESSOR** sessions to choose from:  
**Meeting 1:**  
James H. Doroshow, National Cancer Institute (NCI), USA  
Josep Tabernero, Vall d’Hebron (VHIO), Spain; President (ESMO), Switzerland

**Meeting 2:**  
Richard L. Schilsky, American Society of Clinical Oncology (ASCO), USA  
John Mendelsohn, The University of Texas, MD Anderson Cancer Center, USA

**Meeting 3:**  
Ellen V. Sigal, Friends of Cancer Research, USA

**Meeting 4:**  
Carl H. June, Perelman School of Medicine, USA  
Laura Esserman, University of California San Francisco, USA

**Meeting 5:**  
Francesco De Lorenzo, European Cancer Patient Coalition (ECPC), Belgium

---

**TUESDAY JUNE 26, 2018**

**SESSION 3:** DISRUPTIVE CONCEPTS AND CLINICAL TRIALS SHIFTING THE PARADIGM OF PRECISION ONCOLOGY  
**Chairs:** Carl H. June, Perelman School of Medicine, USA; Richard L. Schilsky, ASCO, USA

| **Keynote Lecture:** | The tri-antibody methodology for blocking the cancer cells: perspectives  
Yosef Yarden, Weizmann Institute of Science, Israel |
|---------------------|--------------------------------------------------|
|                     | The first targeted agents tri-therapy combination trial in first therapeutic line of metastatic NSCLC: the WIN Consortium SPRING_01 trial  
Razelle Kurzrock, University of California San Diego (UCSD), USA |
|                     | The challenges of combining targeted therapies in biomarker driven Precision Oncology – a Pharma perspective  
Jean-François Martini, Pfizer Inc., USA |
|                     | MY-pathway study: when biology meets the challenges of Precision Oncology  
Mary Beattie, Genentech, USA |

**SESSION 4:** NEW CONCEPTS AND THERAPEUTICS AVENUES IN PRECISION ONCOLOGY  
**Chair:** Alan Spatz, McGill Segal Cancer Center, Canada

| **Keynote Lecture:** | Precision CAR T-cells therapeutics  
Carl H. June, Perelman School of Medicine, 2017 David A. Karnofsky Memorial Award ASCO®, USA |
|---------------------|----------------------------------------------------------------------------------|
|                     | The systems biology approach to Precision Oncology: ready to defeat cancer  
Leroy Hood, Institute for Systems Biology (ISB), USA |
|                     | Immunotherapies turning cold in hot tumors  
Jean-Charles Soria, MedImmune, USA |
|                     | Precision Oncology approaches for immunotherapy  
Eric Rubin, Merck, USA |

www.winsymposium.org
**SESSION 5: TOWARDS A NEW MODEL OF DRUG DEVELOPMENT: THE COMBINATION OF TARGETED THERAPIES**

**Chair:** to be confirmed

<table>
<thead>
<tr>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>The great hits of Precision Oncology</td>
<td>Bernadette Toner, GenomeWeb, USA</td>
</tr>
<tr>
<td>Access of patients to Precision Oncology</td>
<td>Francesco De Lorenzo, European Cancer Patient Coalition (ECPC), Belgium</td>
</tr>
</tbody>
</table>

**Roundtable and panel discussion**

<table>
<thead>
<tr>
<th>Moderators:</th>
<th>Panel:</th>
</tr>
</thead>
<tbody>
<tr>
<td>To be confirmed</td>
<td>Francesco De Lorenzo, ECPC, Belgium</td>
</tr>
<tr>
<td></td>
<td>Bernadette Toner, GenomeWeb, USA</td>
</tr>
</tbody>
</table>

**SESSION 6: 10th YEAR OF THE WIN SYMPOSIUM IN THE ERA OF MODERN ONCOLOGY**

**Chairs:** Vladimir Lazar; Catherine Bresson, WIN Consortium, France

**2 best posters presentations and awards**

**10th ANNIVERSARY CEREMONY OF THE WIN SYMPOSIUM**

**WIN AWARDS:**
- Outstanding career
- Best speaker at WIN symposia
- Best project manager
- Best principal investigator
- Best scientific contribution
- Innovation in Precision Oncology
- Friends of WIN